✦ LIBER ✦

A spirituality for the long haul: Response to chronic illness

✍ Scribed by Maureen H. Muldoon; J. Norman King

Publisher: Springer
Year: 1991
Tongue: English
Weight: 690 KB
Volume: 30
Category: Article
ISSN: 0022-4197
DOI: 10.1007/bf00988699

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Selecting a rating scale for evaluating

Selecting a rating scale for evaluating services to the chronically mentally Ill

✍ Rex S. Green; Edward J. Gracely 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 880 KB

Mind's response to the body's betrayal:

Mind's response to the body's betrayal: Gestalt/existential therapy for clients with chronic or life-threatening illnesses

✍ Suzanne A. Imes; Pauline Rose Clance; Andra T. Gailis; Ellen Atkeson 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

## Abstract In the literature on chronic or life‐threatening illness, there is an overriding emphasis on clients' psychological coping styles and how they relate to psychological functioning. By contrast, in our approach, we look at the subjective mind/body experiences that clients have of their il

A closed form solution for the response

A closed form solution for the response of a long elastic beam to dynamic loading

✍ Mittal, R. K. 📂 Article 📅 1989 🏛 Springer-Verlag ⚖ 494 KB

The Perceived Adjustment to Chronic Illn

The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials

✍ Christoph Hürny; Jürg Bernhard; Marisa Bacchi; Brigitte Wegberg; Michele Tomamic 📂 Article 📅 1993 🏛 Springer-Verlag 🌐 English ⚖ 920 KB

Subjective well-being is a major aspect of quality of life and is therefore increasingly used as an endpoint in clinical trials. It is influenced to a great extent by the complex process of coping with the disease and its treatment. Assessment of coping is methodologically demanding, especially in l

Variants in interferon-alpha pathway gen

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

✍ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-␣) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may

Lymphoblastoid interferon alfa-n1 improv

Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial

✍ Geoffrey C. Farrell; Bruce R. Bacon; Robert D. Goldin 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

The aim of this study was to compare the short-term and long-term efficacy and safety of lymphoblastoid interferon with a recombinant interferon alfa (IFN-␣) in a 24-week treatment course for chronic hepatitis C. One thousand seventy-one patients with chronic hepatitis C were randomized to receive l